Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab

• Status: Recruiting
• Trial end date: 2026-02-01
• Target enrollment: 0
• Participant gender: All

Summary

A study on the effectiveness and safety of haploidentical hematopoietic stem cell transplantation in patients with MRD positive CD19+ ALL treated with conditioning regimens containing Blinatumomab

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhejiang University
• Treatments: Blinatumomab

Criteria

Inclusion Criteria:

1. Diagnosed as acute B-ALL with CD19+ according to the 2022 WHO classification criteria. After induction and intensified chemotherapy, complete hematological remission was achieved, but MRD was positive by flow cytometry;

2. Age range from 18 to 70 years old, regardless of gender;

3. The Eastern Oncology Collaborative Group (ECOG) physical fitness score is 0-2 points;

4. Female patients of childbearing age who had a negative pregnancy test before the trial and agreed to take effective contraceptive measures during the trial until their last visit;

5. Organ function is normal, and the following laboratory indicators are met within one week of enrollment: creatinine clearance rate ≥ 60 mL/min (according to the Cockcroft Fault formula); AST and ALT ≤ 3 × Upper limit of normal value range (ULN), total bilirubin ≤ 2 × ULN; Echocardiography (ECHO) shows left ventricular ejection fraction (LVEF) ≥ 50%;

6. Life expectancy greater than 8 weeks;

7. Voluntarily sign an informed consent form to understand and comply with the requirements of the study.

Exclusion Criteria:

1. Failure to achieve complete hematological remission, including residual extramedullary infiltration;

2. Previously received hematopoietic stem cell transplantation;

3. Received systemic chemotherapy within 2 weeks;

4. Previously received treatment with Blinatumomab;

5. Have a history of central nervous system leukemia or present with central nervous system leukemia;

6. Active autoimmune diseases, such as SLE, rheumatoid arthritis, etc;

7. Currently suffering from clinically significant active cardiovascular diseases, such as uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease determined according to the New York Heart Association (NYHA) functional classification (see Appendix 1), or having a history of myocardial infarction within 6 months prior to screening;

8. Chronic obstructive pulmonary disease with whole lung dysfunction;

9. Other serious diseases that may restrict patients from participating in this test (such as advanced infection, uncontrollable diabetes);

10. Concomitant arteriovenous thrombosis or hypercoagulable state;

11. Known human immunodeficiency virus (HIV) infection, or chronic infection of hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive) beyond drug control;

12. Pregnant or lactating women;

13. Severe allergies to other monoclonal antibodies in the past;

14. Those who are unable to understand, comply with the research protocol or sign an informed consent form.